Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced that the U.S. Patent and Trademark Office has issued two patents covering its bacteriophage clinical candidates, AP-SA02 and AP-PA02, according to a company press release dated Oct. 7, 2026.

U.S. Patent No. 12,751,983, issued Oct. 6, 2026, covers methods of treating Staphylococcus aureus infections using AP-SA02, which is in development for the adjunct treatment of complicated S. aureus bacteremia caused by MSSA or MRSA. The patent is expected to provide protection until at least February 2041, with potential extensions.

U.S. Patent No. 12,594,312, issued April 7, 2026, covers methods of treating Pseudomonas infections using AP-PA02, which is in development for diseases caused by Pseudomonas infections. Protection extends to approximately January 2043, including 617 days of patent term adjustments, with potential for further extensions.

With these additions, Armata's global intellectual property portfolio consists of 101 issued patents — 15 in the U.S. and 86 outside the U.S. — along with 60 pending patent applications, with nominal expiration dates through 2046. The portfolio spans 15 patent families.

CEO Deborah Birx said the patents "strengthen our programs in Staphylococcus aureus and Pseudomonas aeruginosa" and reflect the company's strategy of protecting each phage cocktail developed on its proprietary platform. She noted that AP-SA02 is scheduled to enter a Phase 3 superiority study in the second half of 2026. AP-SA02 has received Qualified Infectious Disease Product, Fast Track, and Breakthrough Therapy designations from the FDA.

AP-PA02 has shown results in two Phase 2 clinical trials targeting chronic respiratory infections due to Pseudomonas aeruginosa in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis.